CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, IFNα treatment proved beneficial in chronic myeloid leukemia, based on increased differentiation of CML cells to DC [30], and increased numbers of tumor-specific CD8+ T cells [31], which could also be the result of the increased differentiation of DC under influence of IFNα.